l-carnitine for cancer patients Carnitine Carnitine, Choline, Cancer, & Cholesterol:

doi: 10.3389/fendo.2019.00329 202 FerlinAArrediBForestaC

Clinical trials in patients with metabolic syndrome reveal that L-Carnitine supplementation of 2 g/day for extended periods (25-50 weeks) significantly reduces fasting blood glucose, HbA1c, homeostatic model assessment-insulin resistance (HOMA-IR), inflammatory markers including C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-), and triglyceride levels

Mayer, A

FDA Status and Ongoing Research Sermorelin had FDA-approved injection products in the 1990s for pediatric growth hormone deficiency and for evaluating GH secretion, but the manufacturer discontinued them and FDA withdrew the NDAs in 2009

doi: 10.1111/j.1432-1033.1995.tb20429.x

doi: 10.1016/j.tips.2024.05.006